cilostazol and Myocardial Infarction studies

Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).

Research Excerpts

Excerpt	Relevance	Reference
"The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype."	9.15	Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011)
"Cilostazol is as effective as aspirin in preventing the aggravation of cerebral arteries in secondary prevention of ischemic stroke."	9.14	Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009)
"To observe the dynamic changes of plasma matrix metalloproteinases (MMPs) and investigate the effect of early or delayed percutaneous coronary intervention (PCI) in the presence or absence cilostazol on left ventricle (LV) remodeling in patients with non-ST elevation myocardial infarction (NSTEMI)."	9.14	[Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction]. ( Chen, LL; Feng, GB; Han, YL; Sun, F; Wang, SL; Yan, CH; Zhao, X, 2010)
"To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication."	9.12	Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021)
"We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting."	9.11	Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005)
"Although antiplatelet therapy with a specific inhibitor of phosphodiesterase-3 cilostazol improves stent patency compared with use of aspirin (ASA) alone, the specific role of cilostazol on platelet aggregation in patients with acute myocardial infarction (AMI) is less well understood."	9.09	Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. ( Ikeda, Y; Isaka, N; Ito, M; Kitai, T; Makino, K; Nakano, T; Nishikawa, M; Okinaka, T; Shiku, H; Tanigawa, T; Ueda, Y, 2000)
"Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction."	9.09	Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. ( Eto, K; Isshiki, T; Kondo, K; Ochiai, M; Oshima, A; Sato, T; Takeshita, S; Yokoyama, N, 1999)
"Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention."	9.01	Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019)
"To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication."	8.90	Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014)
"Cilostazol is more effective than aspirin in the prevention of vascular events secondary to stroke."	8.87	Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011)
" Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel."	8.31	Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023)
"Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients."	7.96	Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020)
"There was no significant difference in the incidence of major adverse cardiac events between temporary adjunctive cilostazol treatment and clopidogrel loading in ST-segment elevation acute myocardial infarction patients."	7.80	Temporary adjunctive cilostazol vs clopidogrel loading for ST-segment elevation acute myocardial infarction. ( Inoue, Y; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Suzuki, S; Tanaka, A, 2014)
" The present study examined whether or not cilostazol reduces the myocardial infarct size, and investigated its mechanism in a rabbit model of myocardial infarction."	7.77	Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. ( Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y, 2011)
"Cilostazol, a phosphodiesterase inhibitor, is an antiplatelet agent with positive chronotropic effect, the impact of which on left ventricular (LV) volume and function in acute myocardial infarction (AMI) was evaluated in the present study."	7.74	Impact of chronotropic effect of cilostazol after acute myocardial infarction: insights from change in left ventricular volume and function. ( Choi, S; Choi, SH; Choi, YJ; Han, KR; Hong, KS; Jung, JH; Lee, N; Lee, SH; Oh, DJ; Park, DG; Rhim, CY, 2007)
"Cilostazol, which was administered to prevent subacute stent thrombosis after percutaneous coronary intervention, might have contributed to the transient intraventricular obstruction."	5.34	Dynamic intraventricular obstruction in acute myocardial infarction with administration of cilostazol. ( Hoyano, M; Maeda, C; Miida, T; Oda, H; Ozaki, K; Takahashi, K; Takayama, T; Tsuchida, K; Yanagawa, T, 2007)
"The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype."	5.15	Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011)
"To observe the dynamic changes of plasma matrix metalloproteinases (MMPs) and investigate the effect of early or delayed percutaneous coronary intervention (PCI) in the presence or absence cilostazol on left ventricle (LV) remodeling in patients with non-ST elevation myocardial infarction (NSTEMI)."	5.14	[Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction]. ( Chen, LL; Feng, GB; Han, YL; Sun, F; Wang, SL; Yan, CH; Zhao, X, 2010)
"Cilostazol is as effective as aspirin in preventing the aggravation of cerebral arteries in secondary prevention of ischemic stroke."	5.14	Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009)
"To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication."	5.12	Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021)
"We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting."	5.11	Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005)
"Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction."	5.09	Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. ( Eto, K; Isshiki, T; Kondo, K; Ochiai, M; Oshima, A; Sato, T; Takeshita, S; Yokoyama, N, 1999)
"Although antiplatelet therapy with a specific inhibitor of phosphodiesterase-3 cilostazol improves stent patency compared with use of aspirin (ASA) alone, the specific role of cilostazol on platelet aggregation in patients with acute myocardial infarction (AMI) is less well understood."	5.09	Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. ( Ikeda, Y; Isaka, N; Ito, M; Kitai, T; Makino, K; Nakano, T; Nishikawa, M; Okinaka, T; Shiku, H; Tanigawa, T; Ueda, Y, 2000)
"Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention."	5.01	Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019)
"Cilostazol seems to decrease total ISR rates in patients undergoing CAS without affecting MI/stroke/death events, both in the early and late settings."	4.93	Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting. ( Aggeli, K; Filis, K; Galyfos, G; Geropapas, G; Sianou, A; Sigala, F, 2016)
"To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication."	4.90	Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014)
"Cilostazol is more effective than aspirin in the prevention of vascular events secondary to stroke."	4.87	Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011)
" Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel."	4.31	Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023)
"Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients."	3.96	Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020)
"Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period."	3.83	Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016)
" While, the incidence of adverse side effects tended to be lower, they were not statistically significant in patients with aspirin plus cilostazol."	3.81	Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004)
"Cilostazol increases the walking distance in patients with intermittent claudication, but there is scarce evidence of any effect on the risk for subsequent ischemic events, bleeding or death."	3.80	Cilostazol and outcome in outpatients with peripheral artery disease. ( Aguilar, E; Esteban, C; Jiménez Caballero, PE; Manzano, L; Monreal, M; Mujal, A; Perez, P; Sánchez Muñoz-Torrero, JF; Sauquillo, JC; Yeste, M, 2014)
"There was no significant difference in the incidence of major adverse cardiac events between temporary adjunctive cilostazol treatment and clopidogrel loading in ST-segment elevation acute myocardial infarction patients."	3.80	Temporary adjunctive cilostazol vs clopidogrel loading for ST-segment elevation acute myocardial infarction. ( Inoue, Y; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Suzuki, S; Tanaka, A, 2014)
"One possible cause of stent thrombosis is an insufficient effect of clopidogrel."	3.77	Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. ( Behr, T; Behr, W; Kuch, B; von Scheidt, W, 2011)
" The present study examined whether or not cilostazol reduces the myocardial infarct size, and investigated its mechanism in a rabbit model of myocardial infarction."	3.77	Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. ( Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y, 2011)
"Cilostazol, a phosphodiesterase inhibitor, is an antiplatelet agent with positive chronotropic effect, the impact of which on left ventricular (LV) volume and function in acute myocardial infarction (AMI) was evaluated in the present study."	3.74	Impact of chronotropic effect of cilostazol after acute myocardial infarction: insights from change in left ventricular volume and function. ( Choi, S; Choi, SH; Choi, YJ; Han, KR; Hong, KS; Jung, JH; Lee, N; Lee, SH; Oh, DJ; Park, DG; Rhim, CY, 2007)
"The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction and ischemic stroke at 6 months after PCI."	2.76	Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-. ( Bae, JH; Bae, JW; Chae, IH; Cho, MC; Kim, HS; Lee, SP; Park, KW; Rha, SW; Suh, JW, 2011)
"Cilostazol is a potent antiplatelet agent with less serious side effects."	2.69	Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999)
" Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events."	2.52	Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015)
"In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb."	2.50	Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014)
"Cilostazol is a generic drug with antiplatelet and antiproliferative effects."	2.48	Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. ( Eisenberg, MJ; Friedland, SN; Shimony, A, 2012)
"The key areas of treatment focus on smoking cessation, exercise rehabilitation, with supervised therapy if possible, cardiovascular risk prevention with antiplatelet drugs, statins and angiotensin converting enzymes, and correction of atherosclerotic risk factors with well-defined targets (LDL less than 1g/L, HDL greater than 0."	2.45	[Peripheral arterial disease with lower limb claudication: Medical treatment]. ( Bui, HT; Hadj Henni, A; Journet, J; Long, A, 2009)
"Cilostazol has been shown to be of benefit in improving walking distance in people with IC."	2.44	Cilostazol for peripheral arterial disease. ( Mikhailidis, DP; Robless, P; Stansby, GP, 2007)
"The Cochrane Peripheral Vascular Diseases Group searched their specialised register (last searched August 2007) and the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3, 2007)."	2.44	Cilostazol for peripheral arterial disease. ( Mikhailidis, DP; Robless, P; Stansby, GP, 2008)
"Levosimendan has vasorelaxant and anti-aggregatory properties."	1.48	Cardioprotective and Anti-Aggregatory Effects of Levosimendan on Isoproterenol-Induced Myocardial Injury in High-Fat-Fed Rats Involves Modulation of PI3K/Akt/mTOR Signaling Pathway and Inhibition of Apoptosis: Comparison to Cilostazol. ( El-Kherbetawy, MK; Makary, S; Tawfik, MK, 2018)
"TAPT after drug-eluting stent implantation in patients with uLMCAD did not improve the long-term clinical outcome when compared with conventional DAPT, although it was a safe strategy."	1.39	Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. ( Choi, RK; Hwang, HK; Lee, HJ; Li, H; Park, JS; Ro, YM; Yu, CW, 2013)
"Cilostazol is a unique antiplatelet drug that has vasodilatory effects and inhibits smooth muscle cell proliferation."	1.36	Cilostazol reduces restenosis after carotid artery stenting. ( Hayakawa, M; Matsumaru, Y; Matsumura, A; Nemoto, S; Takigawa, T, 2010)
"Cilostazol has reduced restenosis and repeat intervention after drug-eluting stent (DES) implantation."	1.36	Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). ( Hong, MK; Kim, JJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2010)
"Treatment with cilostazol (10 microM) for 10 min before ischemia significantly reduced the infarct size from 67."	1.35	6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts. ( Fukasawa, M; Miyazaki, M; Nakaya, H; Nishida, H; Sato, T, 2008)
"Cilostazol, which was administered to prevent subacute stent thrombosis after percutaneous coronary intervention, might have contributed to the transient intraventricular obstruction."	1.34	Dynamic intraventricular obstruction in acute myocardial infarction with administration of cilostazol. ( Hoyano, M; Maeda, C; Miida, T; Oda, H; Ozaki, K; Takahashi, K; Takayama, T; Tsuchida, K; Yanagawa, T, 2007)
" At 7 and 30 days, the composite outcome for the group treated with cilostazol alone and that treated with abciximab in combination with cilostazol did not differ significantly."	1.34	Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting. ( Hong, EH; Kim, MY; Lee, MH; Oh, JM; Park, JE; Shin, WG, 2007)

Research

Studies (71)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Area Under Curve of Serial Cardiac Biomarkers

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (5.63)	18.2507
2000's	16 (22.54)	29.6817
2010's	48 (67.61)	24.3611
2020's	3 (4.23)	2.80

Authors	Studies
Lee, YJ	1
Je, NK	1
Kim, SM	1
Jung, JM	1
Kim, BJ	2
Lee, JS	2
Kwon, SU	1
Kim, W	1
Kim, JS	1
Rha, SW	5
Choi, BG	1
Jang, WY	1
Kang, DO	1
Park, Y	3
Choi, JY	1
Roh, SY	1
Na, JO	1
Choi, CU	1
Kim, EJ	2
Park, CG	2
Seo, HS	2
Choi, SY	1
Byun, JK	1
Cha, J	1
Oh, DJ	3
Jeong, MH	6
Brown, T	1
Forster, RB	1
Cleanthis, M	2
Mikhailidis, DP	4
Stansby, G	2
Stewart, M	2
Lee, CH	1
Lee, JY	3
Park, GM	1
Lee, SW	5
Kim, HS	7
Choi, YJ	2
Nam, CW	1
Cho, JH	1
Shin, WY	1
Seo, JB	1
Choi, SW	1
Lee, JH	1
Min, PK	1
Her, SH	1
Lee, PH	1
Ahn, JM	1
Park, DW	3
Kang, SJ	3
Kim, YH	5
Lee, CW	6
Park, SW	7
Park, SJ	7
Tawfik, MK	1
El-Kherbetawy, MK	1
Makary, S	1
Kaikita, K	1
Yoshimura, H	1
Ishii, M	1
Kudoh, T	1
Yamada, Y	2
Yamamoto, E	1
Izumiya, Y	1
Kojima, S	1
Shimomura, H	1
Tsunoda, R	1
Matsui, K	1
Ogawa, H	1
Tsujita, K	1
Zhao, S	1
Zhong, Z	1
Qi, G	1
Shi, L	1
Tian, W	1
Lee, HJ	2
Yu, CW	1
Hwang, HK	1
Choi, RK	1
Park, JS	1
Li, H	1
Ro, YM	1
Park, KH	2
Lee, KH	1
Sim, DS	3
Yoon, HJ	2
Yoon, NS	2
Kim, KH	2
Park, HW	2
Hong, YJ	2
Kim, JH	4
Ahn, Y	2
Cho, JG	2
Park, JC	2
Kang, JC	2
Park, KW	4
Kang, SH	1
Park, JJ	1
Yang, HM	1
Kang, HJ	3
Koo, BK	3
Park, BE	1
Cha, KS	1
Rhew, JY	1
Jeon, HK	1
Shin, ES	1
Oh, JH	2
Kim, S	2
Hwang, KK	1
Yoon, JH	2
Lee, SY	1
Park, TH	1
Moon, KW	1
Kwon, HM	1
Chae, IH	5
Chen, Y	1
Zhang, Y	1
Tang, Y	1
Huang, X	1
Xie, Y	1
Lee, TM	1
Lin, SZ	1
Chang, NC	1
Tanaka, A	1
Ishii, H	1
Sakakibara, M	1
Okumura, S	1
Jinno, Y	1
Okada, K	1
Suzuki, S	1
Inoue, Y	1
Murohara, T	1
Adamson, P	1
Cruden, NL	1
Song, PS	1
Song, YB	1
Yang, JH	1
Hahn, JY	1
Choi, SH	2
Choi, JH	1
Lee, SH	4
Jang, Y	2
Seung, KB	3
Gwon, HC	1
Chen, J	1
Meng, H	1
Xu, L	1
Liu, J	1
Kong, D	1
Chen, P	1
Gong, X	1
Bai, J	1
Zou, F	1
Yang, Z	1
Li, C	1
Eikelboom, JW	1
Perez, P	1
Esteban, C	1
Sauquillo, JC	1
Yeste, M	1
Manzano, L	1
Mujal, A	1
Jiménez Caballero, PE	1
Aguilar, E	1
Sánchez Muñoz-Torrero, JF	1
Monreal, M	1
Di Minno, G	1
Spadarella, G	1
Cafaro, G	1
Petitto, M	1
Lupoli, R	1
Di Minno, A	1
de Gaetano, G	1
Tremoli, E	1
Bedenis, R	1
Robless, P	3
Guo, J	1
Chen, W	1
Wang, G	1
Zhu, F	1
Galyfos, G	1
Geropapas, G	1
Sigala, F	1
Aggeli, K	1
Sianou, A	1
Filis, K	1
Ueda, H	1
Kido, A	1
Matsuhisa, S	1
Asawa, K	1
Yoshida, N	1
Tsujimoto, M	1
Sasaki, Y	1
Kuga, Y	1
Yamasaki, M	1
Ueda, K	1
Shinohara, S	1
Nishida, Y	1
Noh, Y	1
Lee, J	1
Shin, S	1
Lim, HS	1
Bae, SK	1
Oh, E	1
Kim, GJ	1
Lee, S	1
Xu, LX	1
Chen, KY	2
Liu, T	1
Zheng, XT	1
Jiao, ZQ	1
Xu, Y	1
Li, G	1
Li, YJ	1
Poddar, KL	1
Jin, Z	1
Minami, Y	1
Wang, L	1
Ahn, YK	1
Hong, TJ	1
Kim, YJ	1
Hur, SH	1
Seong, IW	1
Chae, JK	1
Cho, MC	4
Bae, JH	4
Choi, DH	1
Jang, YS	1
Kim, CJ	1
Chung, WS	1
Long, A	1
Bui, HT	1
Journet, J	1
Hadj Henni, A	1
Takigawa, T	1
Matsumaru, Y	1
Hayakawa, M	1
Nemoto, S	1
Matsumura, A	1
Guo, JJ	1
Xu, E	1
Lin, QY	1
Zeng, GL	1
Xie, HF	1
Jeong, YH	2
Hwang, JY	2
Kim, IS	2
Hwang, SJ	2
Kwak, CH	2
Yun, SC	1
Kim, WJ	2
Hong, MK	4
Kim, JJ	4
Croce, K	1
Lee, SP	3
Suh, JW	3
Lee, HY	2
Choi, DJ	2
Bae, JW	3
Kwon, TG	2
Lin, GM	1
Chu, KM	1
Han, CL	1
Ye, Y	3
Perez-Polo, JR	3
Birnbaum, Y	3
Fu, Q	1
Yokoyama, N	2
Takada, K	1
Ishikawa, S	1
Isshiki, T	2
Lee, MG	1
Ko, JS	1
Wang, SL	1
Sun, F	1
Zhao, X	1
Chen, LL	1
Feng, GB	1
Yan, CH	1
Han, YL	1
Cho, YS	1
Youn, TJ	1
Kamal, AK	1
Naqvi, I	1
Husain, MR	1
Khealani, BA	1
Kim, PJ	1
Park, HJ	1
Park, KS	1
Yun, SE	1
Park, JR	1
Koh, EH	1
Behr, T	1
Kuch, B	1
Behr, W	1
von Scheidt, W	1
Bai, Y	1
Murakami, H	1
Iwasa, M	1
Sumi, S	1
Ushikoshi, H	1
Aoyama, T	1
Nishigaki, K	1
Takemura, G	1
Uno, B	1
Minatoguchi, S	1
Reis, F	1
Friedland, SN	1
Eisenberg, MJ	1
Shimony, A	1
Choi, YH	1
Suh, SH	1
Choi, JS	1
Kim, CS	1
Bae, EH	1
Lim, SY	1
Ma, SK	1
Kim, SW	1
Heo, SH	1
Hwang, KJ	1
Chang, DI	1
Geng, DF	1
Liu, M	1
Jin, DM	1
Wu, W	1
Deng, J	1
Wang, JF	1
Castillo, AC	2
Qian, J	2
Ling, S	2
Ye, H	2
Bajaj, M	2
Huisamen, B	1
Yang, TH	1
Jin, HY	1
Choi, KN	1
Do, U	1
Kim, HJ	1
Chung, SR	1
Seo, JS	1
Jang, JS	1
Kim, DK	1
Kim, DS	1
Mintz, GS	1
Song, JM	1
Han, KH	2
Kang, DH	1
Song, JK	1
Hashiguchi, M	1
Ohno, K	1
Nakazawa, R	1
Kishino, S	1
Mochizuki, M	1
Shiga, T	1
Park, JH	1
Kawata, M	1
Kuramoto, E	1
Kataoka, T	1
Saito, A	1
Adachi, K	1
Matsuura, A	1
Sakamoto, S	1
Choi, S	1
Jung, JH	1
Lee, N	1
Park, DG	1
Hong, KS	1
Han, KR	1
Rhim, CY	1
Stansby, GP	2
Ozaki, K	1
Maeda, C	1
Takayama, T	1
Hoyano, M	1
Yanagawa, T	1
Tsuchida, K	1
Takahashi, K	1
Miida, T	1
Oda, H	1
Hong, EH	1
Kim, MY	1
Park, JE	1
Lee, MH	1
Oh, JM	1
Shin, WG	1
Kim, JY	1
Lee, K	1
Shin, M	1
Ahn, M	1
Choe, H	1
Yoo, BS	1
Yoon, J	1
Choe, KH	1
Fukasawa, M	1
Nishida, H	1
Sato, T	2
Miyazaki, M	1
Nakaya, H	1
Sanganalmath, SK	1
Barta, J	1
Takeda, N	1
Kumamoto, H	1
Dhalla, NS	1
Saniabadi, AR	1
Takeich, S	1
Yukawa, N	1
Nakajima, Y	1
Umemura, K	1
Nakashima, M	1
Park, HK	1
Ochiai, M	1
Eto, K	1
Takeshita, S	1
Oshima, A	1
Kondo, K	1
Yoon, Y	1
Shim, WH	1
Lee, DH	1
Pyun, WB	1
Kim, IJ	1
Cho, SY	1
Tanigawa, T	1
Nishikawa, M	1
Kitai, T	1
Ueda, Y	1
Okinaka, T	1
Makino, K	1
Ito, M	1
Isaka, N	1
Ikeda, Y	1
Shiku, H	1
Nakano, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparison of Dual-Antiplatelet and Triple-Antiplatelet Preparation Using P2Y12 Assay in Patients With High On-Treatment Platelet Reactivity Undergoing Stent-Assisted Coil Embolization for An Unruptured Intracranial Aneurysm[NCT03581409]	Phase 4	198 participants (Actual)	Interventional	2018-10-24	Completed
Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734]	Phase 4	3,750 participants (Anticipated)	Interventional	2010-06-30	Recruiting
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]	Phase 4	826 participants (Actual)	Interventional	2016-11-30	Completed
Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent[NCT01261832]	Phase 4	951 participants (Anticipated)	Interventional	2011-07-31	Active, not recruiting
ACCELerated Inhibition of Platelet Aggregation, Inflammation and Ischemia-reperfusion Injury by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome[NCT01354808]	Phase 4	220 participants (Anticipated)	Interventional	2010-07-31	Completed
Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828]	Phase 4	960 participants (Actual)	Interventional	2006-11-30	Completed
Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995]	Phase 4	140 participants (Actual)	Interventional	2012-02-01	Completed
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733]	Phase 4	80 participants (Actual)	Interventional	2009-05-31	Completed
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802]		120 participants (Anticipated)	Interventional	2014-08-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

Percentage of Participants With Periprocedural Myonecrosis

Intervention	Hours*ng/ml (Median)
	Troponin I	creatine kinase-MB isoenzyme
Control C1 (High Platelet Reactivity - no Tirofiban)	38.0	92.7
Control C2 (Low Platelet Reactivity - no Tirofiban)	121.4	185.6
Group A (High Platelet Reactivity - Tirofiban)	197.2	252.5

"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

Article	Year
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. Stroke, 2019, Volume: 50, Issue:12 Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He	2019
Cilostazol for intermittent claudication. The Cochrane database of systematic reviews, 2021, 06-30, Volume: 6 Topics: Aged; Bias; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pento	2021
Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials. Clinical drug investigation, 2019, Volume: 39, Issue:1 Topics: Cilostazol; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarctio	2019
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Current medical research and opinion, 2014, Volume: 30, Issue:1 Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans	2014
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:1 Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M	2015
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Annals of medicine, 2014, Volume: 46, Issue:7 Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int	2014
Cilostazol for intermittent claudication. The Cochrane database of systematic reviews, 2014, Oct-31, Issue:10 Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pentoxifyll	2014
Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2016, Volume: 23, Issue:1 Topics: Angioplasty; Cardiovascular Agents; Carotid Stenosis; Chi-Square Distribution; Cilostazol; Humans; M	2016
[Peripheral arterial disease with lower limb claudication: Medical treatment]. Journal des maladies vasculaires, 2009, Volume: 34, Issue:5 Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Cilostazol; Comorbidity; Diabetes Complications; Dr	2009
Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions. Annals of the New York Academy of Sciences, 2010, Volume: 1207 Topics: Aspirin; Cilostazol; Dipyridamole; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase In	2010
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. The Cochrane database of systematic reviews, 2011, Jan-19, Issue:1 Topics: Asian People; Aspirin; Brain Ischemia; Cause of Death; Cilostazol; Gastrointestinal Hemorrhage; Huma	2011
Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. The American journal of cardiology, 2012, May-15, Volume: 109, Issue:10 Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coronary Restenosis; Global Health; Humans; Incidence; M	2012
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology, 2012, Volume: 122, Issue:3 Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil	2012
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3 Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels;	2004
Cilostazol for peripheral arterial disease. The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1 Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Peripheral	2007
Cilostazol for peripheral arterial disease. The Cochrane database of systematic reviews, 2008, Jan-23, Issue:1 Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Peripheral	2008

Article	Year
Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREA The American journal of cardiology, 2018, 02-15, Volume: 121, Issue:4 Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method	2018
Tailored Adjunctive Cilostazol Therapy Based on CYP2C19 Genotyping in Patients With Acute Myocardial Infarction　- The CALDERA-GENE Study. Circulation journal : official journal of the Japanese Circulation Society, 2018, 05-25, Volume: 82, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Cilostazol; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Gen	2018
Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction. Journal of cardiology, 2014, Volume: 63, Issue:2 Topics: Aged; Cilostazol; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Per	2014
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:9 Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy,	2013
Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial. American heart journal, 2016, Volume: 173 Topics: Aged; Aspirin; Cerebrovascular Disorders; Cilostazol; Dose-Response Relationship, Drug; Drug Therapy	2016
Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction. Cardiovascular therapeutics, 2016, Volume: 34, Issue:4 Topics: Aged; Aspirin; Biomarkers; Chi-Square Distribution; China; Cilostazol; Clopidogrel; Drug Administrat	2016
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. Neuroscience bulletin, 2009, Volume: 25, Issue:6 Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr	2009
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patie Circulation. Cardiovascular interventions, 2010, Feb-01, Volume: 3, Issue:1 Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Vessel Prosthesis Implantation; Cells,	2010
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas Trials, 2010, Aug-24, Volume: 11 Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel	2010
[Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction]. Zhonghua xin xue guan bing za zhi, 2010, Volume: 38, Issue:10 Topics: Aged; Angioplasty, Balloon, Coronary; Cilostazol; Electrocardiography; Female; Humans; Male; Matrix	2010
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3 Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;	2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3 Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;	2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3 Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;	2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3 Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;	2011
Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions. The American journal of cardiology, 2011, Apr-01, Volume: 107, Issue:7 Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Cilostazol; Coronary	2011
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:4 Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin;	2011
Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-. Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:11 Topics: Aged; Brain Ischemia; Calcium Channel Blockers; Cilostazol; Clopidogrel; Death; Drug Antagonism; Dru	2011
Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:10 Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Disease-Free Survival; Drug Therapy, Comb	2012
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI. International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1 Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Midd	2013
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3 Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels;	2004
Comparison of cilostazol and clopidogrel after successful coronary stenting. The American journal of cardiology, 2005, Apr-01, Volume: 95, Issue:7 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female;	2005
Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. International heart journal, 2005, Volume: 46, Issue:1 Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial In	2005
Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:12 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; CD40 Antigens; Cilostazo	2007
Comparison of cilostazol versus ticlopidine therapy after stent implantation. The American journal of cardiology, 1999, Sep-01, Volume: 84, Issue:5 Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo	1999
Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. The American journal of cardiology, 1999, Nov-01, Volume: 84, Issue:9 Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Female; Fibr	1999
Usefulness of cilostazol versus ticlopidine in coronary artery stenting. The American journal of cardiology, 1999, Dec-15, Volume: 84, Issue:12 Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp	1999
Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. The American journal of cardiology, 2000, May-01, Volume: 85, Issue:9 Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial	2000

Article	Year
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. European journal of clinical pharmacology, 2023, Volume: 79, Issue:8 Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hemorrhagi	2023
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart and vessels, 2020, Volume: 35, Issue:9 Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy	2020
Cardioprotective and Anti-Aggregatory Effects of Levosimendan on Isoproterenol-Induced Myocardial Injury in High-Fat-Fed Rats Involves Modulation of PI3K/Akt/mTOR Signaling Pathway and Inhibition of Apoptosis: Comparison to Cilostazol. Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:5 Topics: Animals; Apoptosis; Cilostazol; Diet, High-Fat; Disease Models, Animal; Heart Rate; Inflammation Med	2018
Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. Coronary artery disease, 2013, Volume: 24, Issue:7 Topics: Aged; Cerebrovascular Disorders; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Thromb	2013
Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:2 Topics: Animals; Cilostazol; Heart; Male; Milrinone; Myocardial Infarction; Phosphodiesterase 3 Inhibitors;	2014
Temporary adjunctive cilostazol vs clopidogrel loading for ST-segment elevation acute myocardial infarction. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:2 Topics: Acute Disease; Aged; Cilostazol; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged	2014
Cilostazol in acute myocardial infarction: new tricks for an old drug? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:2 Topics: Cilostazol; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitor	2014
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry. Heart and vessels, 2015, Volume: 30, Issue:4 Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy,	2015
Cilostazol and outcome in outpatients with peripheral artery disease. Thrombosis research, 2014, Volume: 134, Issue:2 Topics: Aged; Cilostazol; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intermittent Claudication; Male;	2014
Acute myocardial infarction after cilostazol use in a patient with systemic lupus erythematosus. International journal of cardiology, 2015, Apr-15, Volume: 185 Topics: Aged; Cilostazol; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Intermittent Claudi	2015
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. PloS one, 2016, Volume: 11, Issue:3 Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human	2016
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation, 2009, Jun-30, Volume: 119, Issue:25 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Combined Modality Therapy; C	2009
Cilostazol reduces restenosis after carotid artery stenting. Journal of vascular surgery, 2010, Volume: 51, Issue:1 Topics: Aged; Angioplasty; Carotid Artery Diseases; Cilostazol; Drug Therapy, Combination; Female; Humans; M	2010
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). American heart journal, 2010, Volume: 159, Issue:2 Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up	2010
Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?". Circulation. Cardiovascular interventions, 2010, Feb-01, Volume: 3, Issue:1 Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chemotherapy, Adjuvant; Cilostazol; C	2010
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). American heart journal, 2010, Volume: 160, Issue:3 Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial	2010
Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting. International heart journal, 2010, Volume: 51, Issue:5 Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Cilostazol; Clopidogr	2010
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation? Journal of cardiology, 2011, Volume: 57, Issue:1 Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie	2011
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clinical research in cardiology : official journal of the German Cardiac Society, 2011, Volume: 100, Issue:10 Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascula	2011
Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. Clinical and experimental pharmacology & physiology, 2011, Volume: 38, Issue:10 Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Decanoic Acids; Disease Models, Animal; Drug Eva	2011
Are threshold levels of signal transduction required for the protective effect of cilostazol against cardiac ischaemia-reperfusion injury? Clinical and experimental pharmacology & physiology, 2011, Volume: 38, Issue:10 Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Humans; Myocardial Infarction; Nitric Oxide; Pot	2011
Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients. Journal of neurology, 2013, Volume: 260, Issue:1 Topics: Adult; Aged; Analysis of Variance; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholester	2013
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:6 Topics: Animals; Blood Glucose; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Melli	2012
Cyclic AMP and PKA: how can a lot of good come from the potentially bad? : editorial to: "phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus" by Y Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:6 Topics: Animals; Cilostazol; Cyclic AMP; Diabetes Mellitus, Type 2; Male; Myocardial Infarction; Phosphodies	2012
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. American journal of physiology. Heart and circulatory physiology, 2013, Jan-01, Volume: 304, Issue:1 Topics: Animals; Blood Glucose; Blotting, Western; Cholesterol; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent	2013
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation, 2004, Feb-24, Volume: 109, Issue:7 Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona	2004
Impact of chronotropic effect of cilostazol after acute myocardial infarction: insights from change in left ventricular volume and function. Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:1 Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Drug	2007
Dynamic intraventricular obstruction in acute myocardial infarction with administration of cilostazol. Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:4 Topics: Acute Disease; Aged; Cilostazol; Coronary Angiography; Coronary Thrombosis; Echocardiography; Electr	2007
Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting. International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:6 Topics: Abciximab; Aged; Angina, Unstable; Antibodies, Monoclonal; Cilostazol; Coronary Angiography; Coronar	2007
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts. The Journal of pharmacology and experimental therapeutics, 2008, Volume: 326, Issue:1 Topics: Animals; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Dose-Response Relationship, Drug;	2008
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction. Canadian journal of physiology and pharmacology, 2008, Volume: 86, Issue:4 Topics: Animals; Arrhythmias, Cardiac; Cilostazol; Disease Models, Animal; Echocardiography; Electrocardiogr	2008
Apo E4/3-rich remnant lipoproteins and platelet aggregation: a case report. Thrombosis and haemostasis, 1998, Volume: 79, Issue:4 Topics: 2-Chloroadenosine; Adenosine Diphosphate; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; A	1998

cilostazol and Myocardial Infarction